P/E ratio for CTI BioPharma (CTIC)

P/E ratio history for CTI BioPharma from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Amgen AMGN	18.8	-220.20%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.3	-191.02%	🇺🇸 USA
Incyte INCY	35.7	-328.06%	🇺🇸 USA
Baxter BAX	5.80	-137.03%	🇺🇸 USA
Eli Lilly LLY	143	-1,015.25%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	-11.0	-29.80%	🇮🇱 Israel
Novartis NVS	26.0	-265.79%	🇨🇭 Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.